Lisa Cook sues Trump over firing attempt, emergency hearing set
Cel-Sci Corp (NYSE:CVM) stock has hit a 52-week low, dropping to $0.31, as the biotechnology company faces a challenging period marked by a significant decrease in its stock value. InvestingPro data reveals a weak financial health score of 1.51, though analysts maintain price targets between $6 and $10, suggesting potential upside despite current challenges. Over the past year, Cel-Sci Corp has seen its stock price plummet, with a 1-year change showing a steep decline of -85.29%. With a beta of 0.67 and a debt-to-equity ratio of 0.98, the company operates with moderate market sensitivity and debt levels. This dramatic drop reflects investor concerns and the hurdles the company has encountered, which have severely impacted its market valuation and investor confidence. As the stock hits this new low, stakeholders are closely monitoring the company’s performance and potential recovery plans. InvestingPro subscribers can access 8 additional key insights about CVM’s financial outlook.
In other recent news, CEL-SCI Corporation has announced the commencement of its Confirmatory Registration Study for Multikine in treating head and neck cancer. This study aims to validate previous Phase 3 results that demonstrated a notable increase in 5-year survival rates for patients treated with Multikine compared to standard care. The study will focus on patients with newly diagnosed resectable stage 3 and 4 head and neck cancer, with enrollment expected to conclude by the second quarter of 2026. In addition to clinical advancements, CEL-SCI has completed a stock offering, raising approximately $5 million to support the continued development of Multikine and other corporate needs. The offering involved over 16 million shares of common stock, facilitated by ThinkEquity. CEL-SCI’s Multikine has been administered to more than 740 patients and holds Orphan Drug designation from the FDA. The company’s strategic focus remains on enhancing the immune response in cancer treatment. These developments reflect CEL-SCI’s ongoing commitment to advancing cancer immunotherapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.